> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zimmer Biomet Lifts 2026 Organic Sales Outlook To 3.0%-3.5% As Knee Sales Fall 2.6%
- URL: https://www.bullished.co/zimmer-biomet-lifts-2026-organic-sales-outlook-to-3-0-3-5-as-knee-sales-fall-2-6-77f888f9/
- Published: 2026-11-04T11:53:20.000Z
- Updated: 2026-11-04T11:53:20.000Z
- Description: Hips, bone cement and surgical products grew in the third quarter while knees declined, and adjusted EPS guidance narrowed to $8.50 to $8.60.
- Author: Matteo Parrino
- Tags: Earnings, ZBH, Industry: Healthcare

Zimmer Biomet, the orthopedic device maker, raised its 2026 organic sales growth forecast to 3.0% to 3.5% from 2.25% to 3.25%, as third-quarter [net sales of $2.063 billion](https://www.sec.gov/Archives/edgar/data/0001136869/000119312526446145/zbh-ex99%5F1.htm?ref=bullished.co) rose 3.7% at constant currency. The company reported the results in an [8-K filed](https://www.sec.gov/Archives/edgar/data/0001136869/000119312526446145/zbh-20261104.htm?ref=bullished.co) Wednesday.

## Hips and surgical lines offset knees

Reported sales grew 3.1%. Hips rose 7.0% at constant currency, the technology and data, bone cement and surgical group climbed 13.0%, and the sports medicine and related group (S.E.T.) rose 7.1%. Knees fell 2.6%.

CEO Ivan Tornos said hips, S.E.T. and the technology group, which he put at two-thirds of the company's book of business, grew at upper single-digit or double-digit rates. He said that gave management "confidence to raise our full-year organic constant-currency sales growth and adjusted EPS guidance."

## Profit slips as adjusted EPS holds

Diluted earnings per share fell 13.8% to $1.00\. Adjusted earnings per share were $1.90, matching the prior-year quarter. Net earnings were $191.6 million, or $362.8 million on an adjusted basis.

Operating profit margin fell to 14.9% from 17.6% a year earlier. Zimmer Biomet generated $560.0 million of operating cash flow and $372.4 million of free cash flow in the quarter.

## The updated 2026 guidance

Zimmer Biomet, which makes knee and hip replacements, sports medicine products and robotic surgery systems, narrowed adjusted EPS guidance to $8.50 to $8.60 from $8.47 to $8.59\. Reported revenue growth is now projected at 4.4% to 4.9%, up from 3.9% to 4.9%. Constant-currency growth is projected at 4.1% to 4.6%.

The organic figure excludes the Paragon 28 acquisition, which added roughly 110 basis points through its one-year anniversary.

Management discusses the quarter and the raised outlook on its investor call Wednesday at 8:30 a.m. ET.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ZIMMER BIOMET HOLDINGS, INC. (ZBH)](https://www.sec.gov/Archives/edgar/data/0001136869/000119312526446145/zbh-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit zbh-ex99\_1.htm — ZIMMER BIOMET HOLDINGS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001136869/000119312526446145/zbh-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR